ArticleACS medicinal chemistry letters2012

Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.

Renato Skerlj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.